These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Subchronic phencyclidine administration alters central vasopressin receptor binding and social interaction in the rat. Tanaka K; Suzuki M; Sumiyoshi T; Murata M; Tsunoda M; Kurachi M Brain Res; 2003 Dec; 992(2):239-45. PubMed ID: 14625062 [TBL] [Abstract][Full Text] [Related]
26. Recent advances in the phencyclidine model of schizophrenia. Javitt DC; Zukin SR Am J Psychiatry; 1991 Oct; 148(10):1301-8. PubMed ID: 1654746 [TBL] [Abstract][Full Text] [Related]
27. Brain NMDA Receptors in Schizophrenia and Depression. Adell A Biomolecules; 2020 Jun; 10(6):. PubMed ID: 32585886 [TBL] [Abstract][Full Text] [Related]
28. Sustained NMDA receptor hypofunction induces compromised neural systems integration and schizophrenia-like alterations in functional brain networks. Dawson N; Xiao X; McDonald M; Higham DJ; Morris BJ; Pratt JA Cereb Cortex; 2014 Feb; 24(2):452-64. PubMed ID: 23081884 [TBL] [Abstract][Full Text] [Related]
29. Effects of NMDA receptor inhibition by phencyclidine on the neuronal differentiation of PC12 cells. Lee E; Williams Z; Goodman CB; Oriaku ET; Harris C; Thomas M; Soliman KF Neurotoxicology; 2006 Jul; 27(4):558-66. PubMed ID: 16580729 [TBL] [Abstract][Full Text] [Related]
30. Phencyclidine (PCP) and dizocilpine (MK801) exert time-dependent effects on the expression of immediate early genes in rat brain. Gao XM; Hashimoto T; Tamminga CA Synapse; 1998 May; 29(1):14-28. PubMed ID: 9552172 [TBL] [Abstract][Full Text] [Related]
32. Augmentation of locomotor activity by chronic phencyclidine is associated with an increase in striatal NMDA receptor function and an upregulation of the NR1 receptor subunit. Hanania T; Hillman GR; Johnson KM Synapse; 1999 Mar; 31(3):229-39. PubMed ID: 10029241 [TBL] [Abstract][Full Text] [Related]
33. A novel analog of olanzapine linked to sarcosinyl moiety (PGW5) demonstrates high efficacy and good safety profile in mouse models of schizophrenia. Gil-Ad I; Portnoy M; Tarasenko I; Bidder M; Kramer M; Taler M; Weizman A Eur Neuropsychopharmacol; 2014 Mar; 24(3):425-36. PubMed ID: 24389121 [TBL] [Abstract][Full Text] [Related]
34. Tolerance to the cataleptic effect of the N-methyl-D-aspartate (NMDA) receptor antagonists in pigeons: cross-tolerance between PCP-like compounds and competitive NMDA antagonists. Lu Y; France CP; Woods JH J Pharmacol Exp Ther; 1992 Nov; 263(2):499-504. PubMed ID: 1432686 [TBL] [Abstract][Full Text] [Related]
35. Phencyclidine administration during neurodevelopment alters network activity in prefrontal cortex and hippocampus in adult rats. Kjaerby C; Hovelsø N; Dalby NO; Sotty F J Neurophysiol; 2017 Aug; 118(2):1002-1011. PubMed ID: 28539393 [TBL] [Abstract][Full Text] [Related]
36. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions. Javitt DC Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858 [TBL] [Abstract][Full Text] [Related]
38. Clozapine, but not haloperidol, prevents the functional hyperactivity of N-methyl-D-aspartate receptors in rat cortical neurons induced by subchronic administration of phencyclidine. Arvanov VL; Wang RY J Pharmacol Exp Ther; 1999 May; 289(2):1000-6. PubMed ID: 10215680 [TBL] [Abstract][Full Text] [Related]
39. Comparison of the patterns of altered cerebral glucose utilisation produced by competitive and non-competitive NMDA receptor antagonists. Sharkey J; Ritchie IM; Butcher SP; Kelly JS Brain Res; 1996 Sep; 735(1):67-82. PubMed ID: 8905171 [TBL] [Abstract][Full Text] [Related]